Vimarsana
Biggest News Aggregation in the World

Page 29 - Valuating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Valuating Today - Breaking & Trending Today

Huawei evaluating Western sanctions on Russia - Vimarsana News

Huawei evaluating Western sanctions on Russia

In the first public appearance since her return to China in September last year after 3 years of detention, Huawei's Chief Financial Officer (CFO) Meng Wanzhou said the company is still evaluating its response to Western sanctions on Russia.

MaaT Pharma Announces First Patient Dosed in Phase 3 'ARES' Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease - Vimarsana News

MaaT Pharma Announces First Patient Dosed in Phase 3 'ARES' Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease

Pivotal Phase 3 clinical trial investigates the efficacy of lead Microbiome Ecosystem Therapy MaaT013 as third-line treatment in patients with steroid-resistant gastrointestinal acute Graft-versus-Host

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura) in Patients With Vitiligo - Vimarsana News

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura) in Patients With Vitiligo

Use of ruxolitinib cream (Opzelura) resulted in further improvement in facial and total body repigmentation at Week 52 Results will be featured as an oral presentation in a late-breaking abstract session

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors - Vimarsana News

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors

Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination

argenx SE: argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis - Vimarsana News

argenx SE: argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration Secondary endpoints show